Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results
Neurocrine Biosciences (Nasdaq: NBIX) announced its first quarter 2022 financial results conference call and webcast scheduled for May 4, 2022, at 5:00 a.m. PT (8:00 a.m. ET).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Neurocrine Biosciences (Nasdaq: NBIX) announced its first quarter 2022 financial results conference call and webcast scheduled for May 4, 2022, at 5:00 a.m. PT (8:00 a.m. ET). The Q1 2022 press release will be made available at 4:30 a.m. PT (7:30 a.m. ET) on the same day. Investors can join via a domestic dial-in number (800-895-3361) or international dial-in number (785-424-1062), using the conference ID: NBIX. The webcast link will be accessible on the Neurocrine Biosciences website, with a replay available for one month.
Positive
- Scheduled conference call for Q1 2022 could indicate good communication with investors.
- Diverse portfolio including FDA-approved treatments and numerous mid-to-late-stage clinical programs.
Negative
- None.
Details
News Market Reaction – NBIX
The recorded move for NBIX in the trading session of this news was +0.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast Scheduled for Wednesday, May 4
SAN DIEGO, April 13, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 4, 2022.
The schedule for the press release and conference call / webcast is as follows:
• Q1 2022 Press Release: | May 4, 2022 at 4:30 a.m. PT / 7:30 a.m. ET |
• Q1 2022 Conference Call: | May 4, 2022 at 5:00 a.m. PT / 8:00 a.m. ET |
• Domestic Dial-In Number: | 800-895-3361 |
• International Dial-In Number: | 785-424-1062 |
• Conference ID: | NBIX |
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, as well as over a dozen mid-to-late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2022-financial-results-301525233.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.